betway必威登陆网址 (betway.com )学报››2023,Vol. 44››Issue (5): 356-360.DOI:10.3969/j.issn.2097-0005.2023.05.007
庄会淑1(), 郭俊2, 崔风华1, 杨志华1, 吴寒3, 刘梦晨3, 张文娟3(
)
收稿日期:
2023-02-10出版日期:
2023-05-25发布日期:
2023-06-14通讯作者:
张文娟作者简介:
庄会淑,硕士,主治医师,研究方向:生殖医学,E-mail:zihaosun2008@163.com。基金资助:
Huishu ZHUANG1(), Jun GUO2, Fenghua CUI1, Zhihua YANG1, Han WU3, Mengchen LIU3, Wenjuan ZHANG3(
)
Received:
2023-02-10Online:
2023-05-25Published:
2023-06-14Contact:
Wenjuan ZHANG摘要:
目的探讨血清吻素(kisspeptin)水平与多囊卵巢综合征(polycystic ovary syndrome,PCOS)的相关性,为PCOS的诊断与治疗提供新思路。方法选取2018年1月至2018年12月在betway必威登陆网址 第二附属医院生殖医学门诊就诊的40例PCOS患者作为研究对象,选取同期就诊的因输卵管因素或男方因素导致不孕的非PCOS患者40例作为对照组。测量患者身高、体质量、腰围、臀围等基本指标,并计算腰臀比(waist‐to‐hip ratio,WHR)与体质量指数;检测患者血液性激素六项及相关生化指标;应用酶联免疫吸附法检测患者血清中吻素水平。结果PCOS组患者WHR显著高于对照组,差异有统计学意义(P< 0.05)。PCOS组血清黄体生成素(luteinizing hormone,LH)水平、黄体生成素/卵泡刺激素(follicle‐stimulating hormone,FSH)、吻素及抗苗勒管激素(anti‐Mullerian hormone,AMH)较对照组显著增高(P< 0.05),而卵泡刺激素水平较对照组偏低,差异均有统计学意义(P< 0.05)。PCOS组空腹胰岛素(fasting insulin,FINS)、空腹血糖(fasting blood glucose,FBG)、稳态模型胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA‐IR)均高于对照组,差异有统计学意义(P< 0.05)。Pearson相关分析显示,吻素和AMH、LH、HOMA‐IR水平呈正相关,差异有统计学意义(r= 0.804,0.907,0.023;P< 0.001,P< 0.001,P= 0.030)。受试者工作特征(receiver operating characteristic,ROC)曲线分析血清吻素水平对PCOS诊断的影响,结果显示,ROC曲线下面积为0.621,95%CI:0.570 ~ 0.704,灵敏度为68.8%,特异度为80.9%,吻素用于预测PCOS的截断值为0.470。结论血清吻素水平升高与PCOS具有相关性,吻素/吻素1受体(kisspeptin 1 receptor,KISS1R)系统过度活跃可能参与了PCOS的病理生理过程。
庄会淑, 郭俊, 崔风华, 杨志华, 吴寒, 刘梦晨, 张文娟. 吻素与多囊卵巢综合征的相关性研究[J]. betway必威登陆网址 (betway.com )学报, 2023, 44(5): 356-360.
Huishu ZHUANG, Jun GUO, Fenghua CUI, Zhihua YANG, Han WU, Mengchen LIU, Wenjuan ZHANG. Study on the correlation between kisspeptin and polycystic ovary syndrome[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(5): 356-360.
指标 | PCOS组 (n= 40) | 对照组 (n= 40) | t/t’ | P |
---|---|---|---|---|
年龄/岁 | 22.21 ± 2.51 | 23.27 ± 2.401 | 1.930 | 0.057 |
身高/m | 1.59 ± 0.66 | 1.60 ± 0.94 | 0.055 | 0.956 |
体质量/kg | 69.12 ± 12.36 | 58.72 ± 8.69 | 4.353 | 0.001 |
腰围/cm | 76.35 ± 12.09 | 75.68 ± 9.86 | 0.271 | 0.787 |
臀围/cm | 99.92 ± 12.08 | 94.38 ± 7.72 | 2.444 | 0.017 |
WHR | 0.85 ± 0.11 | 0.78 ± 0.06 | 3.533 | < 0.001 |
BMI/(kg⋅m-2) | 23.43 ± 3.81 | 22.75 ± 4.37 | 0.741 | 0.460 |
表1PCOS组和对照组之间相关指标比较(xˉ±s)
指标 | PCOS组 (n= 40) | 对照组 (n= 40) | t/t’ | P |
---|---|---|---|---|
年龄/岁 | 22.21 ± 2.51 | 23.27 ± 2.401 | 1.930 | 0.057 |
身高/m | 1.59 ± 0.66 | 1.60 ± 0.94 | 0.055 | 0.956 |
体质量/kg | 69.12 ± 12.36 | 58.72 ± 8.69 | 4.353 | 0.001 |
腰围/cm | 76.35 ± 12.09 | 75.68 ± 9.86 | 0.271 | 0.787 |
臀围/cm | 99.92 ± 12.08 | 94.38 ± 7.72 | 2.444 | 0.017 |
WHR | 0.85 ± 0.11 | 0.78 ± 0.06 | 3.533 | < 0.001 |
BMI/(kg⋅m-2) | 23.43 ± 3.81 | 22.75 ± 4.37 | 0.741 | 0.460 |
生殖内分泌 激素 | PCOS组 (n= 40) | 对照组 (n= 40) | t/t’ | P |
---|---|---|---|---|
FSH/(mIU‧mL-1) | 5.10 ± 1.93 | 8.72 ± 1.67 | 8.970 | < 0.001 |
LH/(mIU‧mL-1) | 7.43 ± 5.31 | 4.46 ± 3.68 | 2.907 | < 0.001 |
E2/(pg‧mL-1) | 38.71 ± 19.52 | 32.66 ± 16.27 | 1.507 | 0.120 |
P/(ng‧mL-1) | 0.68 ± 0.27 | 0.57 ± 0.18 | 2.144 | 0.299 |
TT/(ng‧dL-1) | 22.78 ± 13.41 | 21.52 ± 10.77 | 0.463 | 0.627 |
PRL/(ng‧mL-1) | 15.20 ± 6.3 | 12.30 ± 5.7 | 2.159 | 0.076 |
AMH/(ng‧mL-1) | 5.93 ± 4.93 | 2.33 ± 2.5 | 4.119 | < 0.001 |
表2PCOS组和对照组之间生殖内分泌激素指标的比较
生殖内分泌 激素 | PCOS组 (n= 40) | 对照组 (n= 40) | t/t’ | P |
---|---|---|---|---|
FSH/(mIU‧mL-1) | 5.10 ± 1.93 | 8.72 ± 1.67 | 8.970 | < 0.001 |
LH/(mIU‧mL-1) | 7.43 ± 5.31 | 4.46 ± 3.68 | 2.907 | < 0.001 |
E2/(pg‧mL-1) | 38.71 ± 19.52 | 32.66 ± 16.27 | 1.507 | 0.120 |
P/(ng‧mL-1) | 0.68 ± 0.27 | 0.57 ± 0.18 | 2.144 | 0.299 |
TT/(ng‧dL-1) | 22.78 ± 13.41 | 21.52 ± 10.77 | 0.463 | 0.627 |
PRL/(ng‧mL-1) | 15.20 ± 6.3 | 12.30 ± 5.7 | 2.159 | 0.076 |
AMH/(ng‧mL-1) | 5.93 ± 4.93 | 2.33 ± 2.5 | 4.119 | < 0.001 |
指标 | PCOS组 (n= 40) | 对照组 (n= 40) | t/t’ | P |
---|---|---|---|---|
FBG/(mmol‧L-1) | 4.65 ± 0.30 | 4.33 ± 0.53 | 3.323 | 0.113 |
FINS/(mIU‧L-1) | 14.15 ± 10.51 | 7.48 ± 2.16 | 3.932 | < 0.001 |
HOMA-IR | 2.74 ± 0.14 | 1.46 ± 0.34 | 22.017 | < 0.001 |
TC/(mmol‧L-1) | 4.71 ± 0.62 | 4.65 ± 0.39 | 0.518 | 0.602 |
TG/(mmol‧L-1) | 1.86 ± 0.73 | 1.13 ± 0.59 | 4.919 | 0.017 |
吻素(ng‧mL-1) | 0.601 ± 0.416 | 0.28 ± 0.39 | 3.560 | 0.003 |
表3PCOS组和对照组糖脂代谢指标及吻素水平比较
指标 | PCOS组 (n= 40) | 对照组 (n= 40) | t/t’ | P |
---|---|---|---|---|
FBG/(mmol‧L-1) | 4.65 ± 0.30 | 4.33 ± 0.53 | 3.323 | 0.113 |
FINS/(mIU‧L-1) | 14.15 ± 10.51 | 7.48 ± 2.16 | 3.932 | < 0.001 |
HOMA-IR | 2.74 ± 0.14 | 1.46 ± 0.34 | 22.017 | < 0.001 |
TC/(mmol‧L-1) | 4.71 ± 0.62 | 4.65 ± 0.39 | 0.518 | 0.602 |
TG/(mmol‧L-1) | 1.86 ± 0.73 | 1.13 ± 0.59 | 4.919 | 0.017 |
吻素(ng‧mL-1) | 0.601 ± 0.416 | 0.28 ± 0.39 | 3.560 | 0.003 |
1 | Azziz R. Polycystic ovary syndrome[J]. Obstet Gynecol, 2018, 132(2): 321. |
2 | Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome[J]. Lancet Diabetes Endocrinol, 2022, 10(9): 668. |
3 | Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy[J]. J Steroid Biochem Mol Biol, 2018, 182: 27. |
4 | Padda J, Khalid K, Moosa A, et al. Role of kisspeptin on hypothalamic-pituitary-gonadal pathology and its effect on reproduction[J]. Cureus, 2021, 13(8): e17600. |
5 | Gorkem U, Togrul C, Arslan E, et al. Is there a role for 吻素 in pathogenesis of polycystic ovary syndrome?[J]. Gynecol Endocrinol, 2018, 34(2): 157. |
6 | Khan SH, Chaudhry N. Beyond GnRH, LH and FSH: the role of kisspeptin on hypothalalmic-pituitary gonadal (HPG) axis pathology and diagnostic consideration[J]. J Pak Med Assoc, 2021, 71(7): 1862. |
7 | The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril. 2004,81(1):19. |
8 | Mirza FG, Tahlak MA, Rjeili RB, et al. Polycystic ovarian syndrome (PCOS): does the challenge end at conception?[J]. Int J Environ Res Public Health, 2022, 19(22): 14914. |
9 | Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment[J]. J Clin Endocrinol Metab, 2021, 106(3): e1071. |
10 | Pirotta S, Joham A, Grieger JA, et al. Obesity and the risk of infertility, gestational diabetes, and type 2 diabetes in polycystic ovary syndrome[J]. Semin Reprod Med, 2020, 38(6): 342. |
11 | Teede H, Misso M, Tassone EC, et al. Anti-Müllerian hormone in PCOS: a review informing international guidelines[J]. Trends Endocrinol Metab, 2019, 30(7): 467. |
12 | Zhang X, Zheng Y, Guo Y, et al. The effect of low carbohydrate diet on polycystic ovary syndrome: a meta-analysis of randomized controlled trials[J]. Int J Endocrinol, 2019, 2019: 4386401. |
13 | Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited[J]. Endocr Rev, 2016, 37(5): 467. |
14 | Tsoutsouki J, Patel B, Comninos AN, et al. kisspeptin in the prediction of pregnancy complications[J]. Front Endocrinol (Lausanne), 2022, 13: 942664. |
15 | Tang R, Ding X, Zhu J. 吻素 and polycystic ovary syndrome[J]. Front Endocrinol (Lausanne), 2019, 10: 298. |
16 | Chen X, Mo Y, Li L, et al. Increased plasma metastin levels in adolescent women with polycystic ovary syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2010, 149(1): 72. |
17 | Zarei E, Binabaj MM, Zadeh FM, et al. kisspeptin levels in relation to sex hormone profile among PCOS patients[J]. Ir J Med Sci, 2022, 191(4): 1711. |
18 | Rashad NM, Al-Sayed RM, Yousef MS, et al. kisspeptin and body weight homeostasis in relation to phenotypic features of polycystic ovary syndrome; metabolic regulation of reproduction[J]. Diabetes Metab Syndr, 2019, 13(3): 2086. |
19 | Szeliga A, Rudnicka E, Maciejewska-Jeske M, et al. Neuroendocrine determinants of polycystic ovary syndrome[J]. Int J Environ Res Public Health, 2022, 19(5): 3089. |
20 | Navarro VM. Metabolic regulation of kisspeptin - the link between energy balance and reproduction[J]. Nat Rev Endocrinol, 2020, 16(8): 407. |
21 | Pérez-López FR, Ornat L, López-Baena MT, et al. Circulating kisspeptin and anti-müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression[J]. Eur J Obstet Gynecol Reprod Biol, 2021, 260: 85. |
22 | Kołodziejski PA, Pruszyńska-Oszmałek E, Korek E, et al. Serum levels of spexin and kisspeptin negatively correlate with obesity and insulin resistance in women[J]. Physiol Res, 2018, 67(1): 45. |
[1] | 侯丽君, 韩静静, 黄东辉, 王臻.维生素D治疗对糖尿病前期糖脂代谢及胰岛β细胞功能的影响[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(3): 214-218. |
[2] | 张国庆, 吕蒙, 王月兰.胰岛素抵抗与肾脏疾病关系的研究进展[J]. betway必威登陆网址 (betway.com )学报, 2022, 43(11): 801-804. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||